Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5
$DNAY
Medical Specialities
Health Care
Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | Outperform | Cowen | |
| 10/15/2021 | Outperform | Cowen | |
| 7/13/2021 | $23.00 | Buy | Jefferies |
| 7/13/2021 | Outperform | Cowen & Co. | |
| 7/13/2021 | $30.00 | Overweight | Keybanc |
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
Cowen resumed coverage of Codex DNA with a rating of Outperform
Cowen resumed coverage of Codex DNA with a rating of Outperform
Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D - Telesis Bio Inc. (0001850079) (Subject)
Gainers Quotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. Baudax Bio (NASDAQ:BXRX) shares increased by 84.34% to $4.24. The market value of their outstanding shares is at $2.3 million. Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 49.19% to $18.62. The market value of their outstanding shares is at $29.7 million. TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.85% to $0.78. The company's market cap stands at $10.1 million. Journey Medical (NASDAQ:DERM) shares increased by 20.33% to $1.42. The company's market cap stands at $25.1 million. Nuwellis (N
Wednesday saw 219 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Salesforce (NYSE:CRM). Versus Systems (NASDAQ:VS) is the smallest company on a market cap basis to set a new 52-week low. iBio (AMEX:IBIO)'s stock made the biggest move downwards, diving 50.94% to reach a new 52-week low. SomaLogic (NASDAQ:SLGC) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. Here is a list of stocks that set new 52-week lows on Wednesday: Salesforce (NYSE:CRM) stock achieved a new 52-week low on Wednesday morning, hitting $130.60 and moving
Tuesday's session saw 167 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Salesforce (NYSE:CRM) was the largest, in terms of market cap, to set a new 52-week low. The company with the smallest market cap to set a new 52-week low was Baudax Bio (NASDAQ:BXRX). Durect (NASDAQ:DRRX) shares traded down 851.26% to reach its 52-week low, making it the biggest loser. BRF (NYSE:BRFS) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. Stocks that set new 52-week lows on Tuesday are as follows: Salesforce (NYSE:CRM) shares moved down 1.65% on Tuesday to hit a new 52-week low of $130.91, drifting down 1.65%. PT Telkom Indonesi